Shaily Engineering Plastics (501423) investor relations material

Executive summary

• Achieved strong operational and financial performance in FY 2026, with consolidated revenue rising 26% YoY to ₹990.7 crore, driven by healthcare and industrial segment growth, and new business wins.

• Launched ShailyPen Harmony and Neo injectors for semaglutide in India and global markets, marking entry into regulated markets like Canada and the U.S., and expanded into the global semiconductor supply chain.

• Board approved an enabling resolution to raise up to ₹500 crore annually for financial flexibility, growth, and diversification.

• Strengthened leadership with the appointment of a new COO for healthcare.

• Audited consolidated and standalone financial results for FY26 were approved by the Board, with statutory auditors issuing unmodified (clean) opinions.

Financial highlights

• FY 2026 consolidated revenue rose 26% YoY to ₹990.7 crore; Q4 revenue up 9% YoY to ₹237 crore.

• EBITDA increased 61% YoY to ₹288 crore; EBITDA margin at 29% (up 630 bps YoY); PAT up 83% YoY to ₹170 crore; PAT margin at 17.2% (up 540 bps YoY).

• Cash PAT for FY 2026 at ₹219 crore, up 62% YoY.

• Standalone revenue for FY26 was ₹921 crore; standalone PAT up 128% to ₹161 crore.

• Basic EPS (consolidated) for FY26 was ₹36.97, up from ₹20.29 in FY25.

Outlook and guidance

• Focus on scaling healthcare vertical, expanding Abu Dhabi facility, deepening consumer electronics and semiconductor programs, and restoring growth in consumer home furnishings.

• Projected pen injector capacity utilization to reach 36 million in FY 2027 and 50 million in FY 2028, with further ramp-up as new lines come online.

• Margins expected to remain sustainable and improve year-over-year.

• Board recommended a dividend of ₹3 per fully paid equity share for FY26, subject to shareholder approval.